Researchers have validated a predictive biomarker, PAM50, in non-metastatic prostate cancer, enhancing the ability of clinicians to identify patients who will benefit from hormone therapy. Daniel Spratt from University Hospitals Seidman Cancer Center highlights the molecular parallels between breast and prostate cancers, noting that PAM50 – originally developed for breast cancer – can distinguish between subtypes in prostate cancer. This discovery is set to transform diagnostics and guide personalized treatment decisions for recurrent cases and expand its validation to additional prostate cancer scenarios.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
